NASDAQ:TLRY - Nasdaq - US88688T1007 - Common Stock - Currency: USD
Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 194 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.79% | ||
ROE | -34.64% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 30.88% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.11 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.62 | ||
Quick Ratio | 1.61 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 30.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:TLRY (7/25/2025, 3:11:08 PM)
0.6856
-0.02 (-2.45%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.85 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.26 | ||
P/tB | 1.21 | ||
EV/EBITDA | 30.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.79% | ||
ROE | -34.64% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 30.88% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.11 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 12.7 | ||
Cap/Depr | 27.68% | ||
Cap/Sales | 4.39% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.62 | ||
Quick Ratio | 1.61 | ||
Altman-Z | -0.54 |